Impact of Semaglutide (Ozempic/Wegovy®) on Heart and Muscle Mass
NCT ID: NCT07272837
Last Updated: 2026-01-21
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
50 participants
OBSERVATIONAL
2026-02-01
2028-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
This study involves (3) in-person study visits. At each visit, participants will be asked to:
* Undergo magnetic resonance imaging (MRI) while resting and during exercise to take pictures of their heart, abdomen, and legs.
* Complete tests to assess balance, sit-to-stand, walking speed, and handgrip strength.
* Complete questionnaires (related to demographics, health information, physical activity, and nutrition).
* Have a blood sample collected.
* Have blood ketone levels assessed through two finger pricks.
* Complete three days of food records.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Rebalancing the Fat Content of the Heart and Muscles
NCT07065383
Effect of GLP1 Receptor Agonists on Physical Function, Body Composition, and Markers of Aging in Older Adults
NCT05786521
Effect of Oral Semaglutide on Epicardial and Pericoronary Adipose Tissues in Type 2 Diabetes After Myocardial Infarction
NCT06557811
Semaglutide and Vascular Regeneration
NCT05870462
The Effects of Semaglutide on Body Composition and Performance in Military Personnel
NCT06468748
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Starting semaglutide for type 2 diabetes or weight loss (body mass index ≥27.5kg/m2)
* Able to safely undergo an MRI scan (including meeting the physical requirements for MRI equipment)
Exclusion Criteria
* Major recent heart issues or other severe health conditions
* Concerns related to MRI use (including metal implants, pacemaker, severe claustrophobia)
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Alberta
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Related Links
Access external resources that provide additional context or updates about the study.
Study information and pre-screening survey
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Pro00153724
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.